{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T14:41:01Z","timestamp":1771857661702,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s40261-020-00920-8","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T17:02:36Z","timestamp":1589302956000},"page":"603-615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2045-0784","authenticated-orcid":false,"given":"Ramakrishna","family":"Nirogi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koteshwara","family":"Mudigonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopinadh","family":"Bhyrapuneni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nageswara Rao","family":"Muddana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod Kumar","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh Kumar","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Rasheed","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyothsna","family":"Ravula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satish","family":"Jetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veera Raghava Chowdary","family":"Palacharla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"issue":"27","key":"920_CR1","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMra1500587","volume":"373","author":"TE Scammell","year":"2015","unstructured":"Scammell TE. Narcolepsy. N Engl J Med. 2015;373(27):2654\u201362.","journal-title":"N Engl J Med"},{"issue":"9560","key":"920_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(07)60237-2","volume":"369","author":"Y Dauvilliers","year":"2007","unstructured":"Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369(9560):499\u2013511.","journal-title":"Lancet"},{"issue":"8","key":"920_CR3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.sleep.2012.06.006","volume":"13","author":"P Jennum","year":"2012","unstructured":"Jennum P, Ibsen R, Petersen ER, Knudsen S, Kjellberg J. Health, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partners. Sleep Med. 2012;13(8):1086\u201393.","journal-title":"Sleep Med"},{"issue":"5","key":"920_CR4","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.sleep.2014.02.001","volume":"15","author":"J Black","year":"2014","unstructured":"Black J, Reaven NL, Funk SE, McGaughey K, Ohayon M, Guilleminault C, Ruoff C, Mignot E. The Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findings. Sleep Med. 2014;15(5):522\u20139.","journal-title":"Sleep Med"},{"issue":"2","key":"920_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrd1631","volume":"4","author":"R Leurs","year":"2005","unstructured":"Leurs R, Bakker RA, Timmerman H, de Esch IJ. The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005;4(2):107\u201320.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"920_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0165-6147(98)01201-2","volume":"19","author":"R Leurs","year":"1998","unstructured":"Leurs R, Blandina P, Tedford C, Timmerman H. Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends Pharmacol Sci. 1998;19(5):177\u201383.","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"920_CR7","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/bjp.2008.147","volume":"154","author":"TA Esbenshade","year":"2008","unstructured":"Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol. 2008;154(6):1166\u201381.","journal-title":"Br J Pharmacol"},{"issue":"8","key":"920_CR8","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.bcp.2007.01.002","volume":"73","author":"R Parmentier","year":"2007","unstructured":"Parmentier R, Anaclet C, Guhennec C, Brousseau E, Bricout D, Giboulot T, Bozyczko-Coyne D, Spiegel K, Ohtsu H, Williams M, Lin JS. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol. 2007;73(8):1157\u201371.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"920_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1021\/acs.jmedchem.8b01280","volume":"62","author":"R Nirogi","year":"2019","unstructured":"Nirogi R, Shinde A, Mohammed AR, Badange RK, Reballi V, Bandyala TR, Saraf SK, Bojja K, Manchineella S, Achanta PK, Kandukuri KK, Subramanian R, Benade V, Palacharla RC, Jayarajan P, Pandey S, Jasti V. Discovery and development of n-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride (SUVN-G3031): a novel, potent, selective, and orally active histamine H3 receptor inverse agonist with robust wake-promoting activity. J Med Chem. 2019;62(3):1203\u201317.","journal-title":"J Med Chem"},{"issue":"suppl 1","key":"920_CR10","doi-asserted-by":"publisher","first-page":"A50","DOI":"10.1093\/sleep\/zsz067.119","volume":"42","author":"G Bhayrapuneni","year":"2019","unstructured":"Bhayrapuneni G, Kamuju V, Gandipudi S, Jayarajan P, Abraham R, Bojja K, et al. SUVN-G3031, a novel, potent and selective histamine H3 receptor inverse agonist for the treatment of narcolepsy: preclinical characterization [abstract no. 0120]. Sleep. 2019;42(suppl 1):A50.","journal-title":"Sleep"},{"key":"920_CR11","unstructured":"ICH Harmonized Tripartite Guideline, Guideline for Good clinical practice, E6 (R1), Current Step 4 version, dated 10 June 1996."},{"key":"920_CR12","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2020-0020","author":"R Nirogi","year":"2020","unstructured":"Nirogi R, Ajjala DR, Prakash Padala NS, Kalaikadiban I, Rayapati LP, Chunduru P, Shinde A. LC-MS\/MS method for the quantification of SUVN-G3031, a novel H3 receptor inverse agonist for narcolepsy treatment. Bioanalysis. 2020. https:\/\/doi.org\/10.4155\/bio-2020-0020.","journal-title":"Bioanalysis."},{"key":"920_CR13","unstructured":"US Food Drug Administration. Guidance for Industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in\nadult healthy volunteers. Rockville, MD: Food and Drug Administration; 2005. Available\nfrom:http:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm078932.pdf. Accessed 10 Apr 2020."},{"key":"920_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.sleep.2017.01.002","volume":"33","author":"M Kollb-Sielecka","year":"2017","unstructured":"Kollb-Sielecka M, Demolis P, Emmerich J, Markey G, Salmonson T, Haas M. The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use. Sleep Med. 2017;33:125\u20139.","journal-title":"Sleep Med"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00920-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-020-00920-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00920-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T23:18:53Z","timestamp":1620775133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-020-00920-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["920"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00920-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]},"assertion":[{"value":"12 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was sponsored by Suven Life Sciences Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are employees of Suven Life Sciences Ltd. The authors have no other conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All subjects provided written informed consent. The study was conducted at Quintiles Phase One Services LLC (Overland Park, KS, USA).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study was conducted in compliance with the International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice Guidelines, and the Declaration of Helsinki. The protocols were reviewed and approved by the institutional review board, Midlands Independent Review Board (Overland Park, KS, USA).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}